Bicara Therapeutics Inc. (BCAX)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Bicara Therapeutics Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 25.70 $ — 77% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight –
- Max. EBIT decline < 50% –
- Return on equity > 15% -34.4%
- ROCE > 15% -38.7%
- Expected return > 10% –
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 0.0% failed
- Share count grows by less than 3% a year 1.8% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 413 m net cash passed
- Operating cash flow covers the profits of the last three years 31 m failed
- Return on capital at 15% or higher, or up versus two years ago -38.7% failed
- Insiders hold at least 10% or are net buyers 10.2% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 22.4% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 7
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.48 | -4.08 – -2.52 | 0 | -38.0% | 13 |
| 12/31/2027 | -3.63 | -5.05 – -2.68 | 0 | -4.5% | 12 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.77 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.38 | – | 0 | – | – | -30 | -30 |
| 2025: Q1 | -0.68 | – | 0 | – | – | -28 | -28 |
| 2025: Q2 | -0.50 | – | 0 | – | – | -26 | -26 |
| 2025: Q3 | -0.67 | – | 0 | – | – | -29 | -29 |
| 2025: Q4 | -0.68 | – | 0 | – | – | -24 | -24 |
| 2026: Q1 | -0.93 | – | 0 | – | – | -38 | -38 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2022 | 0 | -38 | -38 | -0.73 | -32 | -17 | 7 |
| 2023 | 0 | -40 | -52 | -1.00 | -46 | 219 | 234 |
| 2024 | 0 | -82 | -68 | -1.25 | -75 | 492 | 569 |
| 2025 | 0 | -156 | -138 | -2.52 | -107 | 401 | 431 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Bicara Therapeutics Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, beschäftigt sich mit der Entwicklung bifunktionaler Therapien für solide Tumore.
| Employees | 103 |
|---|---|
| Headquarters | Boston, MA |
| Address | 116 Huntington Avenue, 02116 Boston, United States |
| Phone | 617 468 4219 |
| Website | bicara.com |
| IPO Date | 13. Sep 2024 |
| ISIN | US0554771032 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Claire Mazumdar Clemon M.B.A., Ph.D. | CEO & Director | 1990 |
| Ryan Cohlhepp Pharm.D. | President, COO & Director | 1977 |
| Ivan Hyep M.B.A. | CFO & Treasurer | 1985 |
| Rachel Frank | Vice President of Investor Relations and Corporate Communications | – |
| Lara S. Meisner J.D. | Chief Legal Officer, Compliance Officer & Corporate Secretary | 1972 |
| Pauline Dufresne | Chief People Officer | – |
| Rachel Salazar | SVP of R&D Strategy and Operations | – |
| Sathish Hasige Ph.D. | Senior VP and Head of Technical Operations & Supply Chain | – |
| Angela Windt | VP & Head of Regulatory Affairs | – |
| Jeltje Schulten M.B.A., M.D. | Senior Vice President of Clinical & Medical Affairs | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 10. Jul 2026 | Mazumdar Claire | Chief Executive Officer | Sell | 28 | 29.68 | 831 |
| 10. Jul 2026 | Mazumdar Claire | Chief Executive Officer | Sell | 9,972 | 28.42 | 283,367 |
| 10. Jul 2026 | Mazumdar Claire | Chief Executive Officer | Other | 10,000 | 3.79 | 37,898 |
| 21. Apr 2026 | Ivan Hyep | CFO | Sell | 9,200 | 23.00 | 211,600 |
| 20. Apr 2026 | Claire Mazumdar | CEO | Sell | 15,000 | 23.61 | 354,150 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.